Cordis Launches Low-Profile Incraft AAA Stent Graft In Europe And Canada
This article was originally published in The Gray Sheet
The J&J division has been talking-up Incraft as a potentially major innovation in the treatment abdominal aortic aneurysms for several years.
You may also be interested in...
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. Newly added devices include a new LimaCorporate should component, US approval of the Incraft aneurysm stent graft and a first-in-class newborn-screening diagnostic.
The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.
Johnson & Johnson is looking to the Nevo sirolimus-eluting stent and entry into fast-growing endovascular device segments, such as the abdominal aortic aneurysm market, to restore growth in its struggling Cordis unit